Abstract
During the last decades, the improvement of our knowledge of the mechanisms responsible for cancer development has led to the introduction of new promising strategies of treatment, based on “molecular targeted” drugs. These drugs are designed to act on specific molecules, identified as major players in the maintenance of the malignant status. The development of inhibitors, mainly monoclonal antibodies and small-molecules, directed against activated oncogenes has been the most widely used approach for this kind of treatment. Among the oncogenes implicated in human cancers, tyrosine kinases play a critical role. This observation, together with the discovery that cancer cells can be dependent for their survival from the continuous expression of activated oncogenes (a concept defined as “oncogene addiction”), has made protein kinases ideal targets for targeted therapy in cancer. As the field of targeted therapies is now rapidly growing and a comprehensive survey would be too wide, this review will thus mainly focus on strategies aimed at inhibiting tyrosine kinases and their signal transduction pathways.
Keywords: Tyrosine kinase, monoclonal antibodies, kinase inhibitors, targeted therapies, cancer therapy
Current Pharmaceutical Design
Title: Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Volume: 16 Issue: 12
Author(s): V. Cepero, J. R. Sierra and S. Giordano
Affiliation:
Keywords: Tyrosine kinase, monoclonal antibodies, kinase inhibitors, targeted therapies, cancer therapy
Abstract: During the last decades, the improvement of our knowledge of the mechanisms responsible for cancer development has led to the introduction of new promising strategies of treatment, based on “molecular targeted” drugs. These drugs are designed to act on specific molecules, identified as major players in the maintenance of the malignant status. The development of inhibitors, mainly monoclonal antibodies and small-molecules, directed against activated oncogenes has been the most widely used approach for this kind of treatment. Among the oncogenes implicated in human cancers, tyrosine kinases play a critical role. This observation, together with the discovery that cancer cells can be dependent for their survival from the continuous expression of activated oncogenes (a concept defined as “oncogene addiction”), has made protein kinases ideal targets for targeted therapy in cancer. As the field of targeted therapies is now rapidly growing and a comprehensive survey would be too wide, this review will thus mainly focus on strategies aimed at inhibiting tyrosine kinases and their signal transduction pathways.
Export Options
About this article
Cite this article as:
Cepero V., Sierra J. R. and Giordano S., Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis, Current Pharmaceutical Design 2010; 16 (12) . https://dx.doi.org/10.2174/138161210791033905
DOI https://dx.doi.org/10.2174/138161210791033905 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Harnessing the Tumor Suppressor Function of FOXO as an Alternative Therapeutic Approach in Cancer
Current Drug Targets Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting CCK Receptors in Human Cancers
Current Topics in Medicinal Chemistry Development and Validation of a Five-immune Gene Pair Signature in Endometrial Carcinoma
Combinatorial Chemistry & High Throughput Screening Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design Metallothioneins and Cancer
Current Protein & Peptide Science Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry An Updated Organic Classification of Tyrosinase Inhibitors on Melanin Biosynthesis
Current Organic Chemistry Anti-TNF Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Targeting Proteasomes with Naturally Occurring Compounds in Cancer Treatment
Current Cancer Drug Targets Radioprotective Effect of Febuxostat Against Testicular Damage Induced by Ionizing Radiation in Mice
Current Radiopharmaceuticals How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment
Current Medicinal Chemistry The Emerging Role of Aromatase Inhibitors in the Adjuvant Management of Breast Cancer
Reviews on Recent Clinical Trials Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Current Pharmaceutical Design Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors
Current Topics in Medicinal Chemistry Targeted Regulation of PI3K/Akt/mTOR/NF-κB Signaling by Indole Compounds and their Derivatives: Mechanistic Details and Biological Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry The Changing Face of HDAC Inhibitor Depsipeptide
Current Cancer Drug Targets The Pharmacological Pathways of GnRH Mediating the Inhibition of Mammary Tumours: Implications in Humans and Domestic Animals
Current Medicinal Chemistry Analysis of the Differences in the Expression of mRNAs and miRNAs Associated with Drug Resistance in Endometrial Cancer Cells Treated with Salinomycin
Current Pharmaceutical Biotechnology